...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer >Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer?
【24h】

Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer?

机译：癌症患者静脉血栓栓塞症长期每天皮下低分子肝素的使用：为什么不再犹豫？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Cancer disease inducing an acquired hypercoagulable state is a well-established feature. Venous thromboembolism (VTE) occurs in 4% to 20% of the patients and is the second cause of mortality in cancer; VTE incidence is four to six times higher in cancer patients compared to other patients. In the last 10 years, important randomised clinical trials have clearly demonstrated that long-term use of daily subcutaneous low molecular weight heparin (LMWH) is more efficient than Vitamin K antagonists to treat VTE in cancer patients. First Italian, then American and more recently French national guidelines recommend the use of LMWH for 3 to 6 months for curative treatment of VTE in cancer patients with a clearly high level (A) of evidence. Despite convincing data, many physicians have not yet modified their clinical practice, doubting the tolerability of such a long period of subcutaneous injections. In fact, LMWH long-term use appears well tolerated and may also increase cancer patient survival. OBJECTIVES: The aim of this review is to present the scientific rationale for long-term daily subcutaneous LMWH in cancer patients, and to reinforce the favourable benefit/tolerance tolerability ratio with this specific antithrombotic strategy.
机译：简介：诱发获得性高凝状态的癌症疾病是一个公认的特征。静脉血栓栓塞症（VTE）发生在4％至20％的患者中，是癌症死亡的第二大原因。与其他患者相比，癌症患者的VTE发病率高出四到六倍。在过去的十年中，重要的随机临床试验清楚地表明，长期使用每日皮下低分子量肝素（LMWH）比治疗癌症患者的VTE更有效。首先是意大利，然后是美国，最近是法国的国家指南建议，在证据水平高（A）的癌症患者中，使用LMWH进行3到6个月的VTE治愈性治疗。尽管有令人信服的数据，但许多医生仍未改变其临床实践，对如此长时间的皮下注射的耐受性表示怀疑。实际上，长期使用LMWH似乎耐受性良好，也可能增加癌症患者的生存率。目的：本综述的目的是为癌症患者提供长期每日皮下低分子肝素的科学依据，并通过这种特定的抗血栓形成策略加强有利的获益/耐受性比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号